Tempus AI and Stemline Therapeutics partner to advance AI-driven ESR1 mutation testing in metastatic breast cancer
Tempus AI, Inc. (NASDAQ: TEM) and Stemline Therapeutics, Inc., a wholly owned subsidiary of the Menarini Group, have announced a collaboration to integrate Tempus Next, ... Read More
ANGLE plc signs deal with AstraZeneca to develop Parsortix-based AR detection assay for prostate cancer studies
In a deal valued at £550,000, ANGLE plc (AIM:AGL, OTCQX:ANPCY), a leading liquid biopsy company specializing in circulating tumor cell (CTC) solutions, has secured an ... Read More
ANGLE plc collaborates with AstraZeneca on cutting-edge cancer detection technology
ANGLE plc, a leading innovator in liquid biopsy and circulating tumour cell (CTC) solutions, has announced a significant supplier agreement with global biopharmaceutical leader AstraZeneca ... Read More
ANGLE plc announces cancer diagnosis breakthrough with DNA molecular analysis
ANGLE plc, a global leader in liquid biopsy technology, has recently achieved a major breakthrough in cancer diagnostics, unveiling results from DNA molecular analysis of ... Read More